PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



StevenSolares Portfolio .pdf


Original filename: StevenSolares_Portfolio.pdf

This PDF 1.6 document has been generated by , and has been sent on pdf-archive.com on 29/01/2019 at 20:42, from IP address 216.158.x.x. The current document download page has been viewed 191 times.
File size: 12 MB (19 pages).
Privacy: public file




Download original PDF file









Document preview


HOME

RESUME

PORTFOLIO

CONCEPTS

STEVENSOLARES
PHONE: 201.595.9155 ARTDIRECTOR EMAIL: STEVEN.SOLARES@GMAIL.COM

THANK YOU

HOME

RESUME

PORTFOLIO

CONCEPTS

THANK YOU

STEVENSOLARES
CONTACT

STEVEN.SOLARES@GMAIL.COM
3 JUNIPER CT, APT 129
CLIFTON, NJ 07014

OBJECTIVE

To obtain a position as a GROUP ART SUPERVISOR in
an environment with opportunity for professional growth.

SKILLS

SOFTWARE
Adobe InDesign | Adobe Photoshop | Adobe Illustrator |
Adobe Acrobat | Microsoft Office

LANGUAGES

MULTILINGUAL
English (Fluent)
Spanish (Fluent)

Bachelor of Fine Arts in Graphic Design: Interactive,
Print & Screen with concentration in Advertising.

HARRISON & STAR | Art Supervisor
MAY 2015-PRESENT NEW YORK, NY
• Works on Merck diabetes brand for the Global & US market
that acquired Merck portfolio of products
• Manages projects from an art perspective for day-to-day
creative needs
• Contributes to concepting on core brand and other agency
business, with multiple ideas proceeding to market research
• Presents frequently during creative reviews, both internal
and client-facing
• Manage multiple projects on multiple brands simultaneously
in a fast-paced deadline-driven environment

CENTRON | Art Director
NOVEMBER 2010-JULY 2012 NEW YORK, NY
• Collaborated with Creative Directors to concept pitches
and tactics that acquired new business
• Launched two successful drugs into the market
• Conceptualized and execute creative strategies for
campaigns for various brands (print and electronic media)
• Designed and rebrand corporate identities
• Manage multiple projects on multiple brands simultaneously
in a fast-paced deadline-driven environment
THERAPEUTIC AREAS: Pain Management, Oncology, Infectious
Diseases, CNS/Neurology and Mental Health

THERAPEUTIC AREAS: Diabetes, Gastroenterology, Infectious
Diseases (HCV & HIV) and Oncology
GREY HEALTHCARE GROUP | Senior Art Director
JULY 2012-MAY 2015 NEW YORK, NY
• Helped launch one of the largest Global & US accounts
at the agency at the time in record time
• Worked on full-scale professional launch for a new hepatitis c
treatment, including both print and digital executions
• Conceptualized and executed print/digital tactics that
exceeded client objectives and expectations
• Collaborated with senior management on multiple pitches
that successfully acquired new business
THERAPEUTIC AREAS: Smoking cessation, Infectious Diseases
(HCV), Pulmonology (COPD) and CNS/Neurology (Schizophrenia)

INTERNSHIP

EDUCATION

ROBERT BUSCH SCHOOL OF DESIGN
KEAN UNIVERSITY | MAY 2010

EXPERIENCE

201.595.9155

THE COUGAR’S BYTE | Creative Arts Specialist
AUGUST 2008-MAY 2010 UNION, NJ KEAN UNIVERSITY
Responsible for designing the weekly school newspaper
Design advertisement campaigns and promotional materials
for departments, organizations and clubs
Took photography of events on and off campus for school
media and promotional use
Helped design the Kean Mobile application campaign
1st iPhone College Application in the state of New Jersey

REFERENCES

AVAILABLE UPON REQUEST

HOME

PORTFOLIO

RESUME

CONCEPTS

SALIX FRANCHISE
URL is: https://www.uceris.com/tablet/hcp
URL is: https://www.aprisorx.com/hcp

GASTROENTEROLOGY—HCP Website Redesign, Savings Cards & Journal Ads

URL is: https://www.uceris.com/foam/hcp

THANK YOU

HOME

PORTFOLIO

RESUME

CONCEPTS

THANK YOU

JANUVIA

0.0.0

1.0
Derivative of: DIAB-1142806-0001: p5

1.1

1.4a

DIAB-1162652-0001: p8A

DIABETES—Hypo Virtual Experience Allows HCP To Experience Virtual Simulations Of Hypoglycemia

Animation Notes:
User can place finger
on slider to move it
left/right to one of
the five percentages.
As slider is dragged
to the right, the
corresponding
people icons fill in
with the purple color.

1.5

DIAB-1162652-0001: p20A

DIAB-1162652-0001: p38A

HOME

RESUME

JANUVIA

DIABETES—ADA Puzzle Is A 3D Game That Allowed HCP To Play A Building Puzzle & Provide Facts Under Each Piece

PORTFOLIO

CONCEPTS

THANK YOU

HOME

RESUME

JANUVIA

DIABETES—ADA Timed Trivia Game Where HCP Completed To Make The Leaderboard & Supporting Materials

PORTFOLIO

CONCEPTS

THANK YOU

PORTFOLIO

RESUME

HOME

KISQALI

INTRODUCTION

EFFICACY

SAFETY &
MONITORING

DOSING

INDICATION
RELATED

RESERVING
KISQALI

ACCESS

IS HERE
CONCERN HANDLER
ClLICK NAVIGATION TO BEGIN
Indication
KISQALI® (ribociclib) is indicated in combination with an aromatase inhibitor as initial endocrine-based
therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human
epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

THIS INFORMATION IS FOR INTERNAL USE ONLY AND IS NOT TO BE LEFT WITH, DETAILED FROM,
OR SHOWN TO ANYONE OUTSIDE OF NOVARTIS PHARMACEUTICALS CORPORATION.

ONCOLOGY—Unbranded iPad Detail Aid, Journal Ad, Reprint Carrier & Dosing Mailer

FAQ

CONCEPTS

THANK YOU

HOME

RESUME

OLYSIO

INFECTIOUS DISEASE—Unbranded Websites (Desktop & Mobile), Journal Ad & Convention Promotional Materials

PORTFOLIO

CONCEPTS

THANK YOU

HOME

CHANTIX
CHANTIX

SMOKING CESSATION—Consumer Websites (Desktop & Mobile)

RESUME

PORTFOLIO

CONCEPTS

THANK YOU

HOME

RESUME

DACOGEN

ONCOLOGY—Detail Aid, Journal Ad, Reprint Carrier, Email, Dosing Mailer & Supporting Materials

PORTFOLIO

CONCEPTS

THANK YOU

HOME

RESUME

SEASIDE THERAPEUTICS

GENETICS—Corporate Branding, Clinical Trial Branding, Franchise Website, Corporate Brochures & Supporting Materials

PORTFOLIO

CONCEPTS

THANK YOU

PORTFOLIO

RESUME

HOME

CONCEPTS

STEGLATRO & STEGLUJAN

AND NEEDS ADDITIONAL A1C LOWERING

VERTIS SITA

ADVERSE REACTIONS

DOSING

AFFORDABILITY

ADDITIONAL INFO

BW

LS mean change from baseline A1C, %

FPG

Placebo

0.0
–0.1
–0.2
–0.3
–0.4
–0.5
–0.6
–0.7
–0.8
–0.9
–1.0

STEGLATRO 5 mg

STEGLATRO 15 mg

–0.2

–0.7
N=152; BL=8.0%

SBP

DIFFERENCE FROM PLACEBO, %

–0.8

N=155; BL=8.1%

N=152; BL=8.0%

–0.5 (P<0.001)

–0.6 (P<0.001)

N includes all randomized and treated patients with a baseline measurement
of the outcome variable. At week 26, the primary A1C end point was
missing for 10%, 11%, and 7% of patients, and during the trial, rescue
medication was initiated by 16%, 1%, and 2% of patients randomized to
placebo, STEGLATRO 5 mg, and STEGLATRO 15 mg, respectively. Missing
week 26 measurements were imputed using multiple imputation with a mean
equal to the baseline value of the patient. Results include measurements
collected after initiation of rescue medication. For those patients who did
not receive rescue medication and had values measured at 26 weeks, the
mean changes from baseline for A1C were –0.2%, –0.8%, and –0.9% for
placebo, STEGLATRO 5 mg, and STEGLATRO 15 mg, respectively.
STEGLATRO™ (ertugliflozin) 5 mg and 15 mg tablets
b
Intent-to-treat analysis using ANCOVA adjusted for baseline value, prior
antihyperglycemic
baseline
eGFR.
PATIENTmedication,
PROFILE andVERTIS
SITA2
VERTIS SITA
ADVERSE REACTIONS
DOSING
AFFORDABILITY





ADDITIONAL INFO

Currently on metformin and sitagliptin
and is working on lifestyle modi�cations
such as diet and exercise
A1C not at goal and requires additional
therapy due to disease progression1,2
a N includes all randomized and treated patients with a baseline measurement of the
outcome variable. At week 26, the primary A1C end point was missing for 10%, 11%,
and 7% of patients, and during the trial, rescue medication was initiated by 16%, 1%,
and 2% of patients randomized to placebo, STEGLATRO 5 mg, and STEGLATRO 15
mg, respectively. Missing week 26 measurements were imputed using multiple
imputation with a mean equal to the baseline value of the patient. Results include
measurements collected after initiation of rescue medication. For those patients who
did
di not receive rescue medication and had values measured at 26 weeks, the mean
changes from baseline
1,2for A1C were –0.2%, –0.8%, and –0.9% for placebo,
STEGLATRO 5 mg, and STEGLATRO 15 mg, respectively.

STEGLATRO� (ertugli�ozin) is indicated as an ad�unct to diet and exercise to improve
glycemic control in adults with type 2 diabetes mellitus. STEGLATRO is not recommended in
patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Reference: 1. �agogo-�ack S, Liu �, Eldor R, et al. Ef�cacy and safety of the addition of ertugli�ozin in patients with type 2
diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized
study. Diabetes Obes Metab. 2018;20(3):530–540.

Reference: 1. Dagogo-�ack S, Liu �, Eldor R, et al. Ef�cacy and safety of the addition of ertugli�ozin in patients with type 2
diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized
study. Diabetes Obes Metab. 2018;20(3):530–540.

SELECTED SAFETY INFORMATION

SELECTED SAFETY INFORMATION (continued)

SELECTED SAFETY INFORMATION

eGFR, estimated glomerular �ltration rate.
References: 1. American Diabetes Association. Standards of Medical
Care in Diabetes. Diabetes Care. 2018;41(suppl 1):S1–S159. 2.
DeFronzo RA. From the triumvirate to the ominous octet: a new
paradigm for the treatment of type 2 diabetes mellitus. Diabetes.
2009;58(4):773–795.

SUMMARY

STUDY DESIGN
As an

adjunct to diet and exercise for
appropriate adults with type 2 diabetes

POWER FORWARD

STEGLATRO is indicated as an adjunct to diet and exercise
to improve glycemic control in adults with type 2 diabetes
mellitus.
STEGLATRO is not recommended in patients with type 1
diabetes mellitus or for the treatment of diabetic ketoacidosis.

Actor

Indications and
Selected Safety Information
portrayal.

SGLT2, sodium glucose co-transporter 2.

Contraindications: STEGLATRO is contraindicated in patients with severe renal impairment, end-stage renal disease, or on dialysis,
and/or a history of a serious hypersensitivity reaction to ertugliflozin.
Hypotension: STEGLATRO causes intravascular volume contraction. Symptomatic hypotension may occur after initiating STEGLATRO,
particularly in patients with impaired renal function (estimated glomerular filtration rate [eGFR] less than 60 mL/min/1.73 m2), elderly
patients (≥65 years), patients with low systolic blood pressure, or patients on diuretics. Before initiating STEGLATRO, volume status
should be assessed and corrected if indicated. Monitor for signs and symptoms after initiating therapy.
Ketoacidosis: Ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, has been reported in patients with
type 1 and type 2 diabetes receiving sodium glucose co-transporter 2 (SGLT2) inhibitors, including STEGLATRO. Some cases were

STEGLUJAN™ (ertugliflozin and sitagliptin) 5 mg/100 mg, 15 mg/100 mg tablets
VERTIS SITA

VERTIS FACTORIAL

ADVERSE
REACTIONS

DOSING

AFFORDABILITY

As an adjunct to diet and exercise for appropriate adults with type 2 diabetes

STEGLUJAN—STATISTICALLY SIGNIFICANT REDUCTIONS IN A1C AT WEEK 26 IN AN
INITIAL COMBINATION STUDY OF ERTUGLIFLOZIN AND SITAGLIPTIN
0.0

Placebo

Ertugliflozin 5 mg +
sitagliptin 100 mg

Ertugliflozin 15 mg +
sitagliptin 100 mg

–0.2

WEIGHT

SBP

–0.4
LS mean change from
baseline A1C, %

A1C

–0.6
–0.8

–0.6

–1.0

Primary end point: A1C change from baseline at week 26a,b
a

N includes all randomized and treated patients with a baseline measurement of the outcome variable. At week 26 the primary
A1C end point was missing for 22%, 7%, and 10% of patients, and during the trial, rescue medication was initiated by 32%,
6%, and 0% of patients randomized to placebo, ertugliflozin 5 mg, and ertugliflozin 15 mg, respectively. Missing week 26
measurements were imputed using multiple imputation with a mean equal to the baseline value of the patient. Results included
measurements collected after initiation of rescue medication. For those subjects who did not receive rescue medication and had
values measured at 26 weeks, the mean change from baseline for A1C was −0.8%, −1.7%, and −1.7% for placebo, ertugliflozin
5 mg, and ertugliflozin 15 mg, respectively.

b Intent-to-treat

–1.2

analysis using ANCOVA adjusted for baseline value, prior antihyperglycemic medication, and baseline eGFR.

STEGLUJAN™ (ertugliflozin and sitagliptin) 5 mg/100 mg, 15 mg/100 mg tablets

ANCOVA, analysis of covariance; BL, baseline; eGFR, estimated glomerular filtration rate; LS, least squares; SBP, systolic blood pressure.

–1.4
–1.6

–1.6

–1.8

–1.5

–2.0
N=96; BL=9.0%

N=98; BL=8.9%

N=96; BL=9.0%

DIFFERENCE FROM
PLACEBO, %

–1.0 (P<0.001)

–0.9 (P<0.001)

HOME

PATIENT PROFILE

MOA

VERTIS SITA

VERTIS FACTORIAL

ADVERSE
REACTIONS

DOSING

AFFORDABILITY

As an adjunct to diet and exercise for appropriate adults with type 2 diabetes

HENRY NEEDS POWERFUL A1C

STUDY DESIGN

LOWERING

SELECTED SAFETY INFORMATION (continued)
Urosepsis and Pyelonephritis: Serious urinary tract infections, including urosepsis and pyelonephritis, requiring hospitalization have been
Gender: inMale
identified in patients receiving SGLT2 inhibitors. Cases of pyelonephritis also have been reported
ertugliflozin-treated patients in clinical
trials. Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate patients for signs and symptoms of urinary tract
Age: 57
infections and treat promptly.

9.0% studies with another SGLT2 inhibitor.
Lower Limb Amputations: An increased risk for lower limb amputation has been observedA1C:
in clinical
Across seven Phase 3 clinical trials with ertugliflozin, nontraumatic lower limb amputations
were reported
Weight:
228 lb in 1 (0.1%) patient in the
comparator group, 3 (0.2%) patients in the ertugliflozin 5-mg group, and 8 (0.5%) patients in the ertugliflozin 15-mg group. A causal
association between ertugliflozin and lower limb amputation has not been definitively established.
initiating m
STEGLUJAN,
consider
2
eGFR: 93 Before
mL/min/1.73
factors that may predispose patients to the need for amputations. Monitor patients and discontinue STEGLUJAN if complications occur.
Counsel patients about the importance of routine preventative foot care.

Actor
portrayal.

eGFR, estimated glomerular filtration rate.

Prescribing Information

Indications and Selected Safety Information

SELECTED SAFETY INFORMATION (continued)
Hypotension: Ertugliflozin causes intravascular volume contraction. Symptomatic hypotension may occur after initiating STEGLUJAN,
particularly in patients with impaired renal function (estimated glomerular filtration rate [eGFR] less than 60 mL/min/1.73 m2), elderly
patients (≥65 years), in patients with low systolic blood pressure, or patients on diuretics. Before initiating STEGLUJAN, volume status should
be assessed and corrected if indicated. Monitor for signs and symptoms after initiating therapy.
Ketoacidosis: Ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, has been reported in patients with type 1
and type 2 diabetes receiving sodium glucose co-transporter 2 (SGLT2) inhibitors, including STEGLUJAN. Some cases were fatal. Assess
patients with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level. If ketoacidosis is suspected,
STEGLUJAN should be discontinued, patients should be evaluated, and prompt treatment should be instituted. Before initiating STEGLUJAN,
consider risk factors for ketoacidosis, including pancreatic insulin deficiency from any cause, caloric restriction, and alcohol abuse. In
patients treated with STEGLUJAN, consider monitoring for ketoacidosis and temporarily discontinuing STEGLUJAN in clinical situations known
to predispose to ketoacidosis (eg, prolonged fasting due to acute illness or surgery).
Prescribing Information

Indications and Selected Safety Information

DIABETES—Branded iPad Detail Aid, Convention Panels & Co-branded Print Detail Aid

SECONDARY END POINT: CHANGE IN SBP FROM BASELINE
AT WEEK 26

Contraindications: STEGLATRO is contraindicated in patients with severe renal impairment,
end-stage renal disease, or on dialysis, and/or a history of a serious hypersensitivity reaction to
ertugli�ozin.
Hypotension: STEGLATRO causes intravascular volume contraction. Symptomatic hypotension
may occur after initiating STEGLATRO, particularly in patients with impaired renal function
(estimated glomerular �ltration rate �eGFR� less than 60 mL/min/1.73 m2), elderly patients
(≥65 years), patients with low systolic blood pressure, or patients on diuretics. Before initiating
STEGLATRO, volume status should be assessed and corrected if indicated. Monitor for signs
and symptoms after initiating therapy.
Ketoacidosis: Ketoacidosis, a serious life-threatening condition requiring urgent hospitalization,
has been reported in patients with type 1 and type 2 diabetes receiving sodium glucose
co-transporter 2 (SGLT2) inhibitors, including STEGLATRO. Some cases were fatal. Assess patients
with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level.
If ketoacidosis is suspected, STEGLATRO should be discontinued, patients should be evaluated,
and prompt treatment should be instituted. Before initiating STEGLATRO, consider risk factors for
ketoacidosis, including pancreatic insulin de�ciency from any cause, caloric restriction, and
STEGL
alcohol abuse. In patients treated with STEGLATRO,
consider monitoring for ketoacidosis and
temporarily discontinuing STEGLATRO in clinical situations known to predispose to ketoacidosis
(eg, prolonged fasting due to acute illness or surgery).

Acute Kidney Injury and Impairment in Renal Function: STEGLATRO causes
intravascular volume contraction and can cause renal impairment. There have been postmarketing
reports of acute kidney injury, some requiring hospitalization and dialysis, in patients receiving
SGLT2 inhibitors. Before initiating STEGLATRO, consider factors that may predispose patients to
acute kidney injury. Consider temporarily discontinuing STEGLATRO in any setting of reduced oral
intake or �uid losses; monitor patients for signs and symptoms of acute kidney injury. If acute
kidney injury occurs, discontinue STEGLATRO promptly and institute treatment.
STEGLATRO increases serum creatinine and decreases eGFR. Patients with moderate renal
STEGL
impairment (eGFR 30 to less than 60 mL/min/1.73 m2) may be more susceptible to these
changes. Renal function abnormalities can occur after initiating STEGLATRO. Renal function
should be evaluated prior to initiating STEGLATRO and periodically thereafter. Use of STEGLATRO
is not recommended when eGFR is persistently between 30 and less than 60 mL/min/1.73 m2
and is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m2.
Urosepsis and Pyelonephritis: There have been postmarketing reports of serious urinary
tract infections, including urosepsis and pyelonephritis, requiring hospitalization in patients
receiving SGLT2 inhibitors. Cases of pyelonephritis also have been reported in patients treated
with STEGLATRO in clinical trials. Treatment with SGLT2 inhibitors increases the risk for urinary
tract infections. Evaluate patients for signs and symptoms of urinary tract infections and treat
promptly, if indicated.

Selected Safety Information continues on the next screen.
Before prescribing STEGLATRO, please read the accompanying Prescribing
Information. The Medication Guide also is available.

Selected Safety Information continues on the next screen.

DIAB-1231890-0000.
Selected
Safety Information continues on the next screen.

Before prescribing STEGLATRO, please read the accompanying Prescribing
Information. The Medication Guide also is available.

Before prescribing STEGLATRO, please read the accompanying Prescribing
SELECTED
Information. The Medication
Guide SAFETY
also isINFORMATION
available.

PATIENT PROFILE

ADDED TO METFORMIN
AND SITAGLIPTIN

ADDED TO METFORMIN

SELECTED SAFETY INFORMATION
Indications and Selected Safety Information

Prescribing Information

MOA

SECONDARY END POINT: CHANGE IN BODY WEIGHT FROM
BASELINE AT WEEK 261,2

a N includes all randomized and treated patients with a baseline measurement of the
outcome variable. At week 26, the primary A1C end point was missing for 10%, 11%,
and 7% of patients, and during the trial, rescue medication was initiated by 16%, 1%,
and 2% of patients randomized to placebo, STEGLATRO 5 mg, and STEGLATRO 15
mg, respectively. Missing week 26 measurements were imputed using multiple
imputation with a mean equal to the baseline value of the patient. Results include
measurements collected after initiation of rescue medication. For those patients who
did
di not receive rescue medication and had values measured at 26 weeks, the mean
changes from baseline for A1C were –0.2%, –0.8%, and –0.9% for placebo,
STEGLATRO 5 mg, and STEGLATRO 15 mg, respectively.

Actor
portrayal.

SELECTED SAFETY INFORMATION

PATIENT PROFILE

S��n��c�n� re��c���ns �n ���� �e���� �n� SB� ��en ���e� �� �e�f�r��n �n� s���������n

STEGLATRO is not
indicated for weight loss.

INDICATION

Acute Kidney Injury and Impairment in Renal Function: STEGLATRO causes intravascular volume contraction and can cause renal
impairment. There have been postmarketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients
STEGLATRO
a powerful
receiving SGLT2 inhibitors. Before initiating STEGLATRO, consider factors that may
predisposeispatients
to acute kidney injury.
SGLT2
thatmonitor
helps patients for signs and
Consider temporarily discontinuing STEGLATRO in any setting of reduced oral intake
or inhibitor
fluid losses;
patientspromptly
improveand
glycemic
symptoms of acute kidney injury. If acute kidney injury occurs, discontinue STEGLATRO
institute treatment.
control with proven
STEGLATRO increases serum creatinine and decreases eGFR. Patients with moderate renal impairment (eGFR 30 to less than 60 mL/
reductions in A1C.
min/1.73 m2) may be more susceptible to these changes. Renal function abnormalities can occur after initiating STEGLATRO. Renal function
should be evaluated prior to initiating STEGLATRO and periodically thereafter. Use of STEGLATRO is not recommended when eGFR is
persistently between 30 and less than 60 mL/min/1.73 m2 and is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m2.

HOME

STEGLATRO: ADDITIONAL EFFICACY BENEFITS BEYOND A1C1,2

ADDED TO METFORMIN AND SITAGLIPTIN1

Treatment considerations

ANCOVA, analysis of covariance; BL, baseline; BW, body weight; eGFR, estimated glomerular
filtration rate; FPG, fasting plasma glucose; LS, least squares; SBP, systolic blood pressure.

Prescribing Information

As an adjunct to diet and exercise for appropriate adults with type 2 diabetes

eGFR 85 mL/min/1.73 m2

a

SELECTED SAFETY INFORMATION

As an adjunct to diet and exercise for appropriate adults with type 2 diabetes

significant A1C REDUCTIONS WITH STEGLATRO

Weight 210 lb

A1C REDUCTIONS WITH STEGLATRO ADDED TO METFORMIN AND SITAGLIPTIN3

PRIMARY END POINT: A1C CHANGE FROM BASELINE AT WEEK 26a,b

A1C

ADDED TO METFORMIN
AND SITAGLIPTIN

A1C 8.2%

SUMMARY

As an adjunct to diet and exercise for appropriate adults with type 2 diabetes

POWERFUL

PRIMARY END POINT: A1C CHANGE FROM BASELINE AT WEEK 26a,b

Age 56

STEGLATRO (ertugliflozin) 5 mg and 15 mg tablets
VERTIS SITA2

As an adjunct to diet and exercise for appropriate adults with type 2 diabetes

significant A1C REDUCTIONS WITH STEGLATRO

ADDED TO METFORMIN AND SITAGLIPTIN1

Gender Male



PATIENT PROFILE

ADDED TO METFORMIN
AND SITAGLIPTIN

PATIENT PROFILE

Mark IS ON METFORMIN AND SITAGLIPTIN

THANK YOU

AS MONOTHERAPY

PATIENT PROFILE

ADDED TO METFORMIN
AND SITAGLIPTIN

ADDED TO METFORMIN

SELECTED SAFETY INFORMATION

AS MONOTHERAPY

Acute Kidney Injury and Impairment in Renal Function: STEGLATRO causes
intravascular volume contraction and can cause renal impairment. There
have been
STEGLATRO
is notpostmarketing
reports of acute kidney injury, some requiring hospitalization and dialysis, in patients receiving
indicated for the
SGLT2 inhibitors. Before initiating STEGLATRO, consider factors that may predispose patients to
of of reduced oral
acute kidney injury. Consider temporarily discontinuing STEGLATRO intreatment
any setting
intake or �uid losses; monitor patients for signs and symptoms of acutehypertension.
kidney injury. If acute
kidney injury occurs, discontinue STEGLATRO promptly and institute treatment.
STEGLATRO increases serum creatinine and decreases eGFR. Patients with moderate renal
STEGL
2
impairment (eGFR 30 to less than 60 mL/min/1.73 m ) may be more susceptible to these
changes. Renal function abnormalities can occur after initiating STEGLATRO. Renal function
should be evaluated prior to initiating STEGLATRO and periodically thereafter. Use of STEGLATRO
is not recommended when eGFR is persistently between 30 and less than 60 mL/min/1.73 m2
and is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m2.
Urosepsis and Pyelonephritis: There have been postmarketing reports of serious urinary
tract infections, including urosepsis and pyelonephritis, requiring hospitalization in patients
BL, baseline;
LS, least
squares; SBP,
systolic
pressure.
receiving
SGLT2
inhibitors.
Cases
ofblood
pyelonephritis
also have been reported in patients treated
1. Dagogo-�ack
S, Liutrials.
�, EldorTreatment
R, et al. Ef�cacy
safety of
the additionincreases
of ertugli�ozin
patients
withReferences:
STEGLATRO
in clinical
withand
SGLT2
inhibitors
theinrisk
for with
urinary
2 diabetes mellitus
inadequately
withand
metformin
and sitagliptin:
the VERTIS
placebo-controlled
tracttype
infections.
Evaluate
patientscontrolled
for signs
symptoms
of urinary
tractSITA2
infections
and treat
randomized study. Diabetes Obes Metab. 2018;20(3):530–540. 2. Data available on request from Merck Professional
promptly,
if indicated.
Services-DAP,
WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package

ADDED TO METFORMIN
AND SITAGLIPTIN
SELECTED SAFETY INFORMATION

HOME

RESUME

Strength to

PORTFOLIO

Extend Life

CONCEPTS

THANK YOU

HOME

RESUME

PORTFOLIO

CONCEPTS

THANK YOU

In higher risk MDS

Response
is CRitiCal

The only HMA FDA-approved for 5-day dosing

HOME

RESUME

PORTFOLIO

CONCEPTS

THANK YOU

IN THE TREATMENT OF AFIB, RECOGNIZE

A HIGHER STANDARD
IN BRAIN PROTECTION
Only Pradaxa Provides:
• 25% superior reduction
of ischemic stroke
vs warfarin

• 59% lower rate of
intracranial bleeding
vs warfarin

2012 ACCP
GUIDELINES
RECOMMEND
ED
For preferen
tial
use over war
farin
in AFib patient
s

Protected by

HOME

RESUME

PORTFOLIO

CONCEPTS

Saving your patients from colon cancer is dramatic enough

Take the drama
out of bowel prep

THANK YOU

PLENVU.
LOWER OVERALL VOLUME.
FEWER STEPS.
MAXIMUM EFFICACY.
Introducing PLENVU, the first and only
1 L PEG ELS formulation that cuts down on
volume, time, and steps, so patients can see
their prep all the way through – and you get
the best view in the house.

LESS DRAMA, BETTER OUTCOMES

HOME

RESUME

PORTFOLIO

CONCEPTS

THANK YOU

YES,
WE’RE #4
We may be fourth to market,
but it doesn’t make us late...
It makes us the latest!

Treat at the 4front

HOME

RESUME

PORTFOLIO

CONCEPTS

THANK YOU

FOR MANNY AND HIS UNCONTROLLED TYPE 2 DIABETES

A1C NUMBERS ARE JUST A PART OF

THE BIGGER PICTURE
The only stops Manny wants to make are passenger pick-ups. Since he’s currently
uncontrolled on metformin alone, he needs an add-on therapy that targets the root
problems of T2D to provide strong A1C lowering and an established tolerability
profile—helping to complete the picture for Manny.

(sitagliptin/metformin
extended-release, MSD)

HOME

RESUME

PORTFOLIO

THANK YOU

CONCEPTS

THANK YOU


Related documents


us pom dosing guide 2016
6 emerging antihypertensive drug classes
stevensolaresportfolio
betmigatest
regulation of firearms
what do we know about how to audit


Related keywords